

RECEIVED
CENTRAL FAX CENTER

JAN 12 2006

FAX TRANSMISSION**DATE:** January 12, 2006**PTO IDENTIFIER:** Application Number 10/690190

Patent Number

Inventor: Leonard Bell**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Xuqiong Wu, Ph.D.**PHONE:** (617) 951-7728**Attorney Dkt. #:** ALXN-P02-059**PAGES (Including Cover Sheet):** 4**CONTENTS:** Supplemental Information Disclosure Statement and PTO Form SB/08 (3 pages)
This Facsimile Cover Sheet (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7728 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLP

One International Place, Boston, Massachusetts 02110-2624

Telephone: (617) 951-7000 **Facsimile:** (617) 951-7050

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: January 12, 2006

Signature: *Mary Jane Di Palma*
(Mary Jane DiPalma)

Docket No.: ALXN-P02-059
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Leonard Bell

Application No.: 10/690190

Confirmation No.: 3662

Filed: October 21, 2003

Art Unit: 1644

For: METHOD OF PROPHYLAXIS AGAINST
LARGE MYOCARDIAL INFARCTIONS

Examiner: Nolan, Patrick J.

RECEIVED
CENTRAL FAX CENTER
JAN 12 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Those documents listed on the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application number 10/047,608, filed January 14, 2002 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Application No.: 10/690190

Docket No.: ALXN-P02-059

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ALXN-P02-059.

Dated: January 12, 2006

Respectfully submitted,

By 

Xuqiong Wu, Ph.D.

Registration No.: 55,745

FISH & NEAVE IP GROUP

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/690190	
			Filing Date	October 21, 2003	
			First Named Inventor	Leonard Bell	
			Art Unit	1644	
			Examiner Name	Nolan, Patrick J.	
Sheet	1	of	1	Attorney Docket Number	ALXN-P02-059

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CJ	Bochenek et al., "Use of Cardiopulmonary Bypass Decreases Leukocyte Count and Activation of the Complement System," <i>Kardiologia Polska</i> 36(2):67-72 (English Abstract only)		
	CK	Gori et al., "Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration," <i>Thromb. Haemost.</i> 81:589-593 (1999)		
	CL	Wei et al., "Cytokine Responses and Myocardial Injury in Coronary Artery Bypass Grafting," <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> 61(2):161-166 (2001)		
	CM	Yilmaz et al., "Effect of Low-dose Methyl Prednisolone on Serum Cytokine Levels Following Extracorporeal Circulation," <i>Perfusion</i> 14(3):201-206 (1999)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--